Prosecution Insights
Last updated: April 19, 2026
Application No. 17/206,835

ORGANIC ELECTROLUMINESCENT COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL COMPRISING THE SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE

Non-Final OA §102§DP
Filed
Mar 19, 2021
Examiner
KUCKLA, ANNA GRACE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Rohm And Haas Electronic Materials Korea Ltd.
OA Round
3 (Non-Final)
49%
Grant Probability
Moderate
3-4
OA Rounds
3y 0m
To Grant
95%
With Interview

Examiner Intelligence

Grants 49% of resolved cases
49%
Career Allow Rate
17 granted / 35 resolved
-11.4% vs TC avg
Strong +46% interview lift
Without
With
+46.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
42 currently pending
Career history
77
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
29.7%
-10.3% vs TC avg
§102
22.6%
-17.4% vs TC avg
§112
24.3%
-15.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 35 resolved cases

Office Action

§102 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Acknowledgment is made of applicant’s claim for foreign priority based on applications KR10-2020-0034422 filed on 03/20/2020, KR10-2020-0147603 filed on 11/06/2020, and KR10-2021-0022715 filed on 02/19/2021. However, none of the certified copies of the priority documents have been received. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 10th, 2026 has been entered. Information Disclosure Statement The Information Disclosure Statement (IDS) filed March 17th, 2026 was considered by the Examiner. Status of Claims Claims 1-22 are pending in the instant application. Claim 1 is amended via the amendment filed March 10th, 2026 and claims 4 and 10-22 are withdrawn. Withdrawn Rejections Applicant’s arguments, filed March 17th, 2025, with respect to 102 rejection have been fully considered and are persuasive. The 102 rejection of claims 1-3 and 5-8 has been withdrawn. Applicant has overcome this rejection by amending claim 1 to remove the option for R1-R4 to be hydrogen. Applicant’s arguments, filed March 17th, 2025, with respect to the double patenting rejection have been fully considered and are persuasive. The double patenting rejection of claims 1-9 has been withdrawn. Applicant has overcome this rejection by successfully filing a terminal disclaimer over U.S. Application No. 17/883, 537. Response to Remarks Applicant’s arguments with respect to the 102 rejection of claims 1-3 and 5-8 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Restriction/Election Applicant’s election without traverse of compound C-14 in the reply filed on November 20th, 2024 is acknowledged. Applicant’s elected species appears free of the prior art. Therefore, the search and examination has been extended according to MPEP 803.02 to include the structural species: PNG media_image1.png 369 354 media_image1.png Greyscale . Since a non-elected species has been found not allowable over the prior art, examination has been limited to claims directed to the elected species, which are presently claims 1-3 and 5-9. Claims 1-3 and 5-9 have been examined to the extent that they are readable on the elected embodiment and the above identified nonelected species. Since the nonelected species has been found not allowable, subject matter not embraced by the elected embodiment or the above identified nonelected species is therefore withdrawn from further consideration. Claims 4 and 10-22 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention or species. Election was made without traverse in reply filed November 20th, 2024. New Claim Objections Claim 9 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims New Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-3 and 5-8 is/are newly rejected under 35 U.S.C. 102(a)(1) as being anticipated by Usui et al (WO 2014/157016, published October 2nd, 2014). Usui teaches the following compound (example 15): PNG media_image1.png 369 354 media_image1.png Greyscale . Regarding claim 1, this compound is embraced by instant formula 1, wherein R1-R4 are (C1-C30)alkyl, R5, R12 and R7-R10 are hydrogen, R6 and R11 are –(L1)a-(Ar1)b, wherein L1 is a single bond, a is 1, b is 1, and Ar1 is -N-(Ar2)(Ar3), wherein Ar2 and Ar3 are substituted or unsubstituted C6 aryl. Regarding claim 2, Ar1 is -N-(Ar2)(Ar3) and L1 is a single bond. Regarding claim 3, the compound above is of formula (1-2). Regarding claim 5, L1 is a single bond. Regarding claim 6, Ar1 is -N-(Ar2)(Ar3) and not a (3- to 30-memebered)heteroaryl, as such the limitations of the claims regarding the (3- to 30-memebered)heteroaryl of Ar1 do not apply to the above compound and as such, the compound reads on the claim. Regarding claim 7, Ar1 in the compound above is -N-(Ar2)(Ar3), and as such, the limitations of the claim regarding the (C6-C30) aryl do not apply to the compound, thus the compound reads on the claim. Regarding claim 8, Ar2 and Ar3 are substituted and substituted phenyl. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anna Grace Kuckla whose telephone number is (703)756-5610. The examiner can normally be reached Monday-Friday 7:30-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.G.K./Examiner, Art Unit 1626 /FEREYDOUN G SAJJADI/Supervisory Patent Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Mar 19, 2021
Application Filed
Nov 20, 2024
Response Filed
Feb 11, 2025
Non-Final Rejection — §102, §DP
Aug 12, 2025
Response Filed
Nov 13, 2025
Final Rejection — §102, §DP
Mar 10, 2026
Request for Continued Examination
Mar 16, 2026
Response after Non-Final Action
Mar 18, 2026
Non-Final Rejection — §102, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12583875
PYRROMETHENE-BORON COMPLEX, COLOR CONVERSION COMPOSITION, COLOR CONVERSION FILM, LIGHT SOURCE UNIT, DISPLAY, AND ILLUMINATION DEVICE
2y 5m to grant Granted Mar 24, 2026
Patent 12577273
SMALL MOLECULE MODULATORS OF GUT BACTERIAL BILE ACID METABOLISM
2y 5m to grant Granted Mar 17, 2026
Patent 12577206
PYRAZOLONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS
2y 5m to grant Granted Mar 17, 2026
Patent 12577240
Antiviral Heteroaryl Ketone Derivatives
2y 5m to grant Granted Mar 17, 2026
Patent 12559492
BRAF DEGRADERS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
49%
Grant Probability
95%
With Interview (+46.4%)
3y 0m
Median Time to Grant
High
PTA Risk
Based on 35 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month